Holy Cross Hospital

Clinical research site in Silver Spring, Maryland · 1500 FOREST GLEN RD, SILVER SPRING, MD 20910-1483 · (301) 754-7246 · Website

Part of Holy Cross Hospital

As of July 2026, 8 paid clinical trials are recruiting at Holy Cross Hospital in Silver Spring, Maryland. Active studies at this site cover conditions such as Carcinoma, Ovarian Epithelial, Endometrial Cancer and Endometrioid Ovarian Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Holy Cross Hospital (8)

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for Ovarian Cancer

38 locations incl. Anchorage

Sponsor: Incyte Corporation

Sex: Female·Age: 18+

Code: NCT07214779·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

81 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

for Lumbar Spinal Stenosis

2343 locations incl. Athens

Sponsor: Stryker Instruments

Sex: All·Age: 18+

Code: NCT03072927·Recruiting·Listed Mar 2017

Apply to this trial

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for Triple Negative Breast Neoplasms

37 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06841354·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

42 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

65 locations incl. Birmingham

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for Platinum-resistant Ovarian Cancer

32 locations incl. Mobile

Sponsor: Genelux Corporation

Sex: Female·Age: 18+

Code: NCT05281471·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

for Solid Tumor, Adult

4 locations incl. Silver Spring

Sponsor: Bio-Path Holdings, Inc.

Sex: All·Age: 18+

Code: NCT04196257·Phase 1·Recruiting·Listed Dec 2019

Apply to this trial

More research sites in Silver Spring

Maryland Oncology Hematology, P.A. (5 trials)
Adventist Healthcare White Oak Medical Center (3 trials)
Maryland Oncology Hematology (3 trials)
Maryland Oncology Hematology - Silver Spring (3 trials)
Food and Drug Administration (2 trials)
Jadestone Clinical Research (2 trials)
Maryland Oncology Hematology P A (2 trials)
TSC Alliance (2 trials)
Holy Cross Hospital - Silver Spring (2 trials)
ACCOMPLISH-1 Research Site (1 trial)

Explore more

Paid clinical trials in Silver Spring, MD · Maryland clinical trials